ABBVIE VENTURES – VISION

Drive strategic returns to AbbVie as a key constituent of overall corporate strategy

- Early access to external innovation with a long-term horizon to generate meaningful enhancements to scientific knowledge in core R&D areas
- Generate financial return through thoughtful, targeted investments in high risk/high reward opportunities
- Create opportunities for future business development
ABBVIE VENTURES – STRATEGY AND VALUE PROPOSITION TO PARTNERS

Strategy
- Primary interest in early stage transformational opportunities in immunoscience, oncology, and neurodegenerative disease, consistent with core R&D strategy
- Evaluate new technologies and other innovation that could have an impact on AbbVie
- CEO commitment to support reliable and consistent investment in portfolio companies and new opportunities

Value Proposition to Co-Investors and Emerging Growth Companies

- Dedicated senior team with significant experience in drug development, discovery and venture investing
- Access to broader AbbVie expertise (commercial, IP, etc.)
- Ability to leverage AbbVie R&D tool-box of drug discovery technologies and development resources
- Bench of experienced R&D, BD and VC professionals as potential board members

ABBVIE VENTURES TEAM

Scott Brun, M.D.
Head, AbbVie Ventures

Margarita Chavez
Senior Director

John Gustofson
Senior Director

Charles Kunsch, Ph.D.
Director

Ross Leimberg
Senior Manager

Priyanka Rohatgi, Ph.D.
Director
### SUMMARY OF VENTURE INVESTMENT AREAS OF PRIMARY FOCUS BY THERAPEUTIC AREA

<table>
<thead>
<tr>
<th>ONCOLOGY</th>
<th>IMMUNOLOGY</th>
<th>NEUROSCIENCE</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Immuno-oncology approaches extending internal efforts (innate immunity, next generation cellular or viral approaches)</td>
<td>- Disruptive innovation to re-establish immune tolerance and immunosuppressive environment</td>
<td>- Platforms supplementing core AD and PD research, including gene therapy</td>
</tr>
<tr>
<td>- Innovation to complement existing biologic expertise (apoptosis, DNA damage repair)</td>
<td>- Leverage microbiome biology for novel targets</td>
<td>- Neuro-protective/neuro-restorative approaches</td>
</tr>
</tbody>
</table>

**PLATFORM TECHNOLOGIES AND BIOLOGIES**
- Biologic pathway targets that support cross TA opportunities
- Novel targeting approaches and modalities

### IMMUNOLOGICAL DISEASE AREAS OF STRATEGIC FOCUS

**Prioritized Thematic Areas of Collaboration Focus in Immunology**

#### RHEUMATOLOGY
- Rheumatoid Arthritis
- Psoriatic Arthritis
- Axial Spondyloarthropathies (Ax SpA)
- Systemic Lupus Erythematosus
- Sjogren's disease

#### CORE AND EMERGING BIOLOGIES

<table>
<thead>
<tr>
<th>T- AND B-CELL BIOLOGY</th>
<th>MYELOID BIOLOGY</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Cytokine signaling</td>
<td>- Myeloid cell trafficking, activation and differentiation</td>
</tr>
<tr>
<td>- Lymphocyte activation and cell migration</td>
<td>- Shifting a pro-inflammatory macrophage to an anti-inflammatory phenotype</td>
</tr>
<tr>
<td>- Co-stimulatory pathways</td>
<td>- Direct inhibition of macrophage to pro-inflammatory phenotype</td>
</tr>
<tr>
<td>- T-regulatory cell activity</td>
<td></td>
</tr>
<tr>
<td>- Immune regulatory cytokines</td>
<td></td>
</tr>
</tbody>
</table>

#### GASTROENTEROLOGY
- Crohn’s Disease
- Ulcerative Colitis

#### EPITHELIAL BIOLOGY AND MUCOSAL HEALING
- Repairing and maintaining epithelial barrier
- Inhibiting aberrant extracellular matrix deposition and tissue remodeling
- Mechanisms involved in fibrosis
- Pattern recognition receptors

#### DERMATOLOGY
- Psoriasis
- Refractory atopic dermatitis

#### MICROBIOME BIOLOGY
- Immune system modulation
- Barrier function maintenance
- Engineered bacteria as delivery systems
ONCOLOGY DISEASE AREAS OF STRATEGIC FOCUS
Prioritized Thematic Areas of Collaboration Focus in Oncology

SOLID TUMORS
HEMATOLOGICAL MALIGNANCIES

CORE BIOLOGY
- Apoptosis
- B cell signaling
- Cancer stem cell biology

IMMUNO-ONCOLOGY
- Mechanisms involved in innate immune responses
- Suppressive tumor microenvironment
- Engineered T-cell specificity/soluble TCR therapeutics
- Antigen presentation

EMERGING BIOLOGY
- Genetically engineered cell based therapies
- Nucleic acid based therapies
- Miniaturized antibody like proteins
- Oncolytic viruses
- Protein homeostasis/degradation

NEUROSCIENCE DISEASE AREAS OF STRATEGIC FOCUS
Prioritized Thematic Areas of Collaboration Focus in Neuroscience

Developing a portfolio of differentiating products in chronic diseases like Alzheimer’s disease, Parkinson’s disease and multiple sclerosis

ALZHEIMER’S DISEASE
PARKINSON’S DISEASE
MULTIPLE SCLEROSIS

ALZHEIMER’S DISEASE
PARKINSON’S DISEASE
MULTIPLE SCLEROSIS

Protein Misfolding and Clearance
(tau emphasis)
Folding/aggregation inhibition/production/clearance

Neuroprotection
Neuroprotection & Neuro-regeneration

Neuro-Immune/neuroinflammation

Metabolic Pathway Dysfunction
Lipid/cholesterol modulation
(ApoE emphasis)

Synaptic Dysfunction

Axonal Growth and Plasticity
ABBVIE VENTURES PORTFOLIO

- DNA damage repair
  - Artios
- Small molecule integrin inhibitors
  - Palleon Pharma
- Translation regulation in cancer
  - Morphic Therapeutic
- Mutagenesis inhibition in cancer
  - Effector
- Gene therapy platform
  - Alector
- Antibodies for neurodegenerative disorders
  - Calimmune
- Natural products discovery engine
  - Aapogen Biotechnologies
- Undisclosed
  - Lodo Therapeutics

Seattle and NY Accelerator

- Recombinant alkaline phosphatase for acute kidney injury
- Oncolytic viruses
  - Exicure
- Gamma-secretase modulator for Alzheimer's disease
  - Genelux Pharmaceuticals
- Spherical nucleic acid platform
  - Undisclosed